Clincosm LogoSign in Get a demo

Association of Epicardial Adipose Tissue Volume Axnd Radiodensity With Coronary Artery Calcification in Patients With HFpEF

Sponsor
Chongqing Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05556785
Collaborator
(none)
200
Enrollment
1
Location
36
Anticipated Duration (Months)
5.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Recruiting patients who were diagnosed with HFpEF. Using Non-contrast CT to measure the total Agatston coronary artery calcification score, epicardial adipose tissue volume and attenuation. Analysing the correlation between them.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study enrolled patients who were diagnosed with HFpEF and admitted to the Cardiology Department of the First Affiliated Hospital of Chongqing Medical University. Using Non-contrast CT to measure the total Agatston coronary artery calcification score, epicardial adipose tissue volume and attenuation. Finally, analysing the correlation between them.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Association of Epicardial Adipose Tissue Volume Axnd Radiodensity With Coronary Artery Calcification in Patients With HFpEF
    Actual Study Start Date :
    Jan 1, 2020
    Anticipated Primary Completion Date :
    Dec 31, 2022
    Anticipated Study Completion Date :
    Dec 31, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Association of epicardial adipose tissue volume axnd radiodensity with coronary artery calcification in Patients with HFpEF [2022.09]

      Using SPSS software to analysis the relationship of epicardial adipose tissue volume axnd radiodensity with coronary artery calcification in Patients with HFpEF

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Typical symptoms and signs of heart failure

    • Left ventricular ejection fraction≥50%

    • HFA-PEFF score≥5

    Exclusion Criteria:
    • severe myocarditis, malignant tumors, liver or renal insufficiency, severe valvular heart disease, and received a bypass surgery or other open-heart surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The First Affiliated Hospital of Chongqing Medical University Chongqing China

    Sponsors and Collaborators

    • Chongqing Medical University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dongying Zhang, Clinical Professor, Chongqing Medical University
    ClinicalTrials.gov Identifier:
    NCT05556785
    Other Study ID Numbers:
    • DZhang
    First Posted:
    Sep 27, 2022
    Last Update Posted:
    Sep 27, 2022
    Last Verified:
    Sep 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Heart Failure
    Calcinosis

    Study Results

    No Results Posted as of Sep 27, 2022